These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29678592)

  • 1. Retina Compatible Interactions and Effective Modulation of Blood Ocular Barrier P-gp Activity by Third-Generation Inhibitors Improve the Ocular Penetration of Loperamide.
    Janga KY; Tatke A; Shukla S; Lamichhane SP; Avula B; Wang X; Jablonski MM; Khan IA; Majumdar S
    J Pharm Sci; 2018 Aug; 107(8):2128-2135. PubMed ID: 29678592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein Restricts Ocular Penetration of Loperamide across the Blood-Ocular Barriers: a Comparative Study in Mdr1a Knock-out and Wild Type Sprague Dawley Rats.
    Tatke A; Janga KY; Avula B; Wang X; Jablonski MM; Khan IA; Majumdar S
    AAPS PharmSciTech; 2018 May; 19(4):1662-1671. PubMed ID: 29520587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood-Brain Barrier.
    Nieto Montesinos R; Béduneau A; Lamprecht A; Pellequer Y
    Mol Pharm; 2015 Nov; 12(11):3829-38. PubMed ID: 26390138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution.
    Montesinos RN; Moulari B; Gromand J; Beduneau A; Lamprecht A; Pellequer Y
    Drug Metab Dispos; 2014 Apr; 42(4):700-6. PubMed ID: 24398461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
    Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
    Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats.
    Müllauer J; Karch R; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Mairinger S; Müller M; Löscher W; Langer O; Kuntner C
    Nucl Med Biol; 2013 Aug; 40(6):755-63. PubMed ID: 23774004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier.
    Choo EF; Kurnik D; Muszkat M; Ohkubo T; Shay SD; Higginbotham JN; Glaeser H; Kim RB; Wood AJ; Wilkinson GR
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1012-8. PubMed ID: 16537797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
    Suzuki K; Taniyama K; Aoyama T; Watanabe Y
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
    Rowbottom C; Pietrasiewicz A; Tuczewycz T; Grater R; Qiu D; Kapadnis S; Trapa P
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00740. PubMed ID: 33660938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    Pharm Res; 2007 Sep; 24(9):1720-8. PubMed ID: 17380257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
    Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
    Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
    Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
    Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
    Fujii S; Setoguchi C; Kawazu K; Hosoya K
    Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.
    Chufan EE; Kapoor K; Ambudkar SV
    Biochem Pharmacol; 2016 Feb; 101():40-53. PubMed ID: 26686578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.
    Hubensack M; Müller C; Höcherl P; Fellner S; Spruss T; Bernhardt G; Buschauer A
    J Cancer Res Clin Oncol; 2008 May; 134(5):597-607. PubMed ID: 17932689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-Glycoprotein on Blood-Brain Barrier Plays a Vital Role in Fentanyl Brain Exposure and Respiratory Toxicity in Rats.
    Yu C; Yuan M; Yang H; Zhuang X; Li H
    Toxicol Sci; 2018 Jul; 164(1):353-362. PubMed ID: 29669042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
    Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
    J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.